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Objective: A potential intracellular mechanism for the protective ffects of 
myocardial preconditioning is the activation of protein kinase C. The 
present study tested the hypothesis that a brief period of protein kinase C 
activation before cardioplegic arrest would provide protective ffects on 
myocyte contractility with subsequent reperfusion and rewarming. Methods: 
Left ventricular porcine myocytes were assigned to the following treat- 
ments: (1) Protein kinase C/cardioplegia: Protein kinase C activation in 
myocytes (n = 39) for 3 minutes with a phorbol ester (10 -9 mol/L of phorbol 
12-myristate 13-acetate) in oxygenated, normothermic (37 ° C) cell media. 
Protein kinase C activation was followed by 2 hours of cardioplegic arrest 
(K +, 24 mEq/L; HCO3-, 30 mEq/L; 4 ° C) and a 5-minute reperfusion period 
(37 ° C media). (2) Cardioplegia: Myocytes (n = 31), 2 hours of cardioplegic 
arrest, and a 5-minute reperfusion and rewarming period. Myocyte con- 
tractility was measured by means of high-speed videomicroscopy. For 
comparison purposes, contractile function was examined in myocytes (n = 
70) under normothermic control conditions. Results: Myocyte shortening 
velocity was reduced after cardioplegic arrest when compared with normo- 
thermic values (22.3 - 1.6 vs 48.8 - 2.0/xm/sec, p < 0.0001). Protein kinase 
C activation before cardioplegic arrest normalized myocyte shortening 
velocity (48.8 - 2.5 #m/sec). Co-incubation with phorbol 12-myristate 
13-acetate and chelerythrine (10 -6 mol/L), an inhibitor of protein kinase C, 
before cardioplegic arrest abolished the protective effects of phorbol 
12-myristate 13-acetate pretreatment. Conclusion: These results suggest 
that an endogenous means of providing improved myocardial protection 
during prolonged cardioplegic arrest can be achieved through a brief period 
of protein kinase C activation. (J Thorac Cardiovasc Surg 1997;114:651-9) 
0 elivery of a hypothermic, hyperkalemic ar- dioplegic solution is a common means to obtain 
myocardial quiescence during cardiac surgical pro- 
cedures. However, transient left ventricular (LV) 
dysfunction can occur with subsequent reperfusion 
and rewarming. Myocardial preconditioning de- 
scribes a phenomenon in which myocardium made 
transiently ischemic becomes more tolerant to a 
subsequent and prolonged period of ischemia. 1-3 
Experimental studies have demonstrated that isch- 
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emic preconditioning before the induction of car- 
dioplegic arrest can improve LV pump function with 
reperfusion and rewarming. 4-6 Identification of the 
intracellular mechanism(s) that invoke the precon- 
ditioning phenomenon may provide important in- 
formation for developing novel strategies for myo- 
cardial protection during prolonged periods of 
cardioplegic arrest. Recent studies have demon- 
strated that activation of the serine-threonine protein 
kinase C (PKC) may be an intracellular triggering 
Received for publication August 6, 1996; revisions requested 
Dec. 5, 1996; revisions received April 21, 1997; accepted for 
publication April 22, 1997. 
Address for reprints: Francis G. Spinale, MD, PhD, Cardiotho- 
racic Surgery, Room 418 CSB, Medical University of South 
Carolina, 171 Ashley Ave., Charleston, SC 29425. 
Copyright © 1997 by Mosby-Year Book, Inc. 
0022-5223/97 $5.00 + 0 12/1/82920 
651 
652 O et al. 
The dournai of Thoracic and 
Cardiovascular Surgery 
October 1997 
mechanism for the preconditioning phenomenon. 7-13 
However, whether and to what extent direct activa- 
tion of PKC at the level of the myocyte provides 
protective ffects in the setting of cardioplegic arrest 
and rewarming remains unknown. Accordingly, the 
present study was designed to test the central hy- 
pothesis that a short interval of PKC activation 
before a prolonged period of hypothermic, hy- 
perkalemic ardioplegic arrest would improve myo- 
cyte contractile function on reperfusion and re- 
warming. 
Pharmacologic activation of PKC has been dem- 
onstrated to occur in the presence of phorbol es- 
ters.7, 10-13 This laboratory has described previously 
that cardioplegic arrest with subsequent reperfusion 
and rewarming can be successfully performed in 
isolated LV myocytes, t4-16 This isolated myocyte 
system provides an uncomplicated means to exam- 
ine cellular and molecular events that occur with 
respect o myocyte contractile processes during car- 
dioplegic arrest and rewarming. Past reports have 
demonstrated that preconditioning can be success- 
fully induced in isolated myocyte systems, t2' 13, 16, 17 
A brief exposure of isolated myocytes to phorbol 
esters has been shown to increase PKC activi- 
ty.t3, t8, t9 Accordingly, the present study used an 
isolated myocyte system of cardioplegic arrest to 
determine whether a short pretreatment interval 
with a phorbol ester and subsequent PKC activation 
would provide protective effects on myocyte con- 
tractile processes. 
Methods 
Rationale. The goal of the present study was to exam- 
ine whether a brief interval of PKC activation before a 
prolonged period of simulated cardioplegic arrest would 
protect myocyte contractile function with rewarming. The 
first series of experiments was designed to develop a 
protocol for PKC activation in this myocyte system by 
examining the time and dose-dependent ffects of phorbol 
ester administration on myocyte contractile function un- 
der steady-state normothermic conditions. The next series 
of experiments examined whether a brief PKC activation 
period before cardioplegic arrest would provide protective 
effects on myocyte contractile function with subsequent 
rewarming. The final series of experiments was performed 
to determine more carefully that the effects of phorbol 
ester treatment on myocyte function were due to specific 
PKC activation. 
Myocyte isolation and contractile function. Adult 
Yorkshire pigs (n = 5) were the source of LV myocytes. 
All animals were treated and cared for in accordance with 
the National Institutes of Health "Guide for the Care and 
Use of Laboratory Animals" (National Research Council, 
Washington, D.C., 1996). The animals were anesthetized 
with isoflurane (2%/1.5 L/min) and their lungs ventilated 
through a nonrecirculating anesthesia circuit. A sternot- 
omy was then performed, and the heart was quickly 
extirpated and placed in cold oxygenated Krebs solution. 
The region of the LV free wall perfused by the left 
circumflex coronary artery (5 × 5 cm) was dissected free, 
cannulated, and prepared for myocyte isolation as de- 
scribed previously. 14-16 In brief, oxygenated modified 
Krebs solution containing aerobic substrates and collage- 
nase (0.5 mg/ml, type II; 146 U/mg, Worthington Bio- 
chemical Corp., Freehold, N.J.) was perfused and recir- 
culated through the cannulated circumflex artery for 20 
minutes. The tissue was then minced into 2 mm sections 
and added to an oxygenated solution containing bovine 
serum albumin (2%, Sigma Chemical Co., St. Louis, Mo.), 
deoxyribonuclease (DNase, 51 Kunitz units/mI, type IV, 
Sigma), CaC12 (400 × 10 .6 mol/L, Sigma), and collage- 
nase (0.5 mg/ml, Worthington) and gently agitated. The 
isolated myocytes were then suspended in fresh culture 
medium (media 199, 2 mmol/L Ca 2÷, Gibco Laboratories, 
Grand Island, N.Y.). A 2 ml aliquot of the isolated 
myocyte suspension (5 × 10 4 cells/ml) was then plated 
onto coverslips previously coated with a laminin/fibronec- 
tin matrix (Matrigel, Collaborative Research, Inc.. Bed- 
ford. Mass.) and incubated at 37°C for 1 hour in the 
presence of 95°A oxygen and 5% carbon dioxide. 
Myocyte contractile function was examined with the use 
of computer-assisted videomicroscopy techniques de- 
scribed previously. 14q6 In brief, myocytes were imaged on 
an inverted microscope (model PIM. World Precision 
Instruments. Sarasota, Fla.) in a 2.5 ml tissue chamber 
with a thermoregulator  maintain media temperature at 
37 ° C. Myocytes were stimulated at 1 Hz and contractions 
were imaged with the use of a charge-coupled device 
(GPCD60, Panasonic. Secaucus, N.J.). Myocyte motion 
signals were input through an edge-detector system (Cres- 
cent Electronics, Sandy, Utah), converted into a voltage 
signal, digitized, and input into a computer (80286, 
ZBV2526. Zenith Data Systems, St. Joseph, Mo.) for 
subsequent analysis. Stimulated myocytes were allowed a 
5-minute stabilization period, after which contraction data 
for each myocyte were recorded for a minimum of 20 
consecutive contractions. Parameters computed from the 
digitized contraction profiles included percent shortening 
(percent), peak velocity of shortening (micrometers per 
second), peak velocity of relengthening (micrometers per 
second), total contraction duration tmilliseconds), time to 
peak contraction (milliseconds), and time to 50% relax- 
ation (milliseconds). 
PKC activation and myocyte contractile function. To 
develop a protocol for PKC activation in isolated myo- 
cytes, we used the initial series of experiments toexamine 
the effects of a phorbol ester, phorbol 12-myristate 13- 
acetate (PMA, Sigma), on myocyte contractile function 
under normothermic conditions. The phorbol ester PMA 
was selected for these studies because it has been dem- 
onstrated previously to activate PKC in isolated myocyte 
preparations la and readily enters the intracellular com- 
partment. Stock PMA was solubilized with 100% ethanol 
(Pharmco Products Inc.. Brookfield. Conn.) and then 
diluted with a Krebs buffer solution. Myocyte contractile 
function and viability were examined before and after 
incubation (3 to 30 minutes) with PMA 110 -6 to 10 -9 
mol/L). In the present study, a significant reduction in 
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myocyte contractile function occurred at 10 -9  mol/L of 
PMA with no change in myocyte viability (Fig, 1). How- 
ever, myocyte viability, as defined in the previous ection, 
was substantially reduced with PMA at concentrations 
greater than 10 -~ mol/L and for incubation intervals 
greater than 10 minutes. Accordingly, incubation of myo- 
cytes with PMA at a concentration of 10 -9  mol/L for 3 
minutes was selected as the pretreatment protocol for the 
simulated cardioplegia experiments. 
Simulated eardioplegic arrest with rewarming 
Effect of PKC activation. The next series of experiments 
was performed to examine whether abrief period of PMA 
pretreatment before cardioplegic arrest would provide 
protective effects on myocyte contractile function on 
rewarming. Isolated myocytes were randomly assigned to 
one of the following treatment groups: (1) incubation in 
oxygenated, normothermic media (37 ° C) for 3 minutes; 
(2) incubation in oxygenated, normothermic media con- 
taining PMA (10 9 mol/L) for 3 minutes; or (3) incubation i  
oxygenated, normothermic media containing vehicle 
(Krebs buffer solution containing equivalent concentra- 
tions of ethanol) for 3 minutes. All myocytes were then 
subjected to simulated cardioplegic arrest as described 
previously] 4-16 Specifically, myocytes were exposed to a 
crystalloM cardioplegic solution (lactated Ringer's solu- 
tion: K +, 24 mEq/L; HCO3-, 30 mEq/L; oxygen tension > 
300 mm Hg) for 2 hours at 4 ° C. After cardioplegic arrest, 
the cardioplegic solution was rapidly changed with nor- 
mothermic ell culture medium. After 5 minutes of nor- 
mothermic reperfusion, steady-state myocyte contractile 
function was examined. The experimental protocol for 
this series of studies is shown in Fig. 2. 
Effects of PKC blockade. A series of experiments was 
performed to examine whether the effects of PMA on 
myocyte contractile function before cardioplegic arrest 
with rewarming were specifically mediated by activation of 
PKC. Chelerythrine (LC Laboratory, Woburn, Mass.) has 
been demonstrated to be a potent (inhibitory concentra- 
tion of 50% [ICso ] = 10 -v tool/L) and specific inhibitor of 
the catalytic domain of PKC. 2° In a past report, cheleryth- 
rine at a concentration of 10 -6 mol/L abolished the 
protective ffects of preconditioning in human atrial tissue 
preparations] Accordingly, myocytes were incubated in 
normothermic, oxygenated media containing both chel- 
erythrine (10 .6 mol/L) and PMA (10 -9 tool/L) together 
for 3 minutes, then subjected to identical treatment as 
described in the previous paragraph. In an additional set 
of experiments, myocytes were exposed to chelerythrine 
(10 .6 mol/L) for 3 minutes and then subjected to  car- 
dioplegic arrest. The experimental protocol for these 
studies is outlined in Fig. 2. 
PKC transloeation in isolated myocytes. A generalized 
intracellular event that occurs after activation of PKC is 
translocation from intracellular cytosolic ompartments to 
the cell membrane. =~=3 Furthermore, it has been demon- 
strated previously that PMA causes PKC translocation i
isolated myocyte preparations. 23 Accordingly, localization 
of PKC in isolated myocytes was performed by means of 
fluorescent echniques. 24 Isolated myocytes from three 
different preparations were assigned to one of the follow- 
ing treatment groups: (1) incubation in oxygenated, nor- 
mothermic media (37 ° C) for 3 minutes; (2) incubation in 
oxygenated, normothermic media containing PMA (10 -9 
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Fig. 1. Effects of PKC activation on myocyte contractile 
function in the presence of the phorbo! ester PMA. The 
purpose of the first series of experiments was to determine 
the dose-dependent ffect of PMA (10 -6 to 10- ~(~ tool/L) on 
myocyte contractile function under normothermic condi- 
tions. In the presence of PMA, a dose-dependent decline in 
steady-state myocyte contractile function was observed with 
a significant reduction occurring at 10 -9 mol/L of PMA. 
Accordingly, 10 .9 mol/L of PMA was selected as the con- 
centration to be used for PKC activation i  isolated myocytes 
for the cardioplegic arrest and rewarming studies. A mini- 
mum number of 15 myocytes were studied at each concen- 
tration of PMA. *p < 0.05 vs no PMA; tP < 0.05 vs [PMA] 
10 lo tool/L; -~p < 0.05 vs [PMA] 10 9 mol/L). 
mol/L) for 3 minutes; and (3) incubation in oxygenated, 
normothermic media containing both chelerythrine (10 -6 
mol/L) and PMA (10 9 mol/L) together for 3 minutes. 
After these treatments, myocytes were fixed in 3.7% 
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Fig. 2. Schematic representation of myocyte treatment protocols. Normothermia is maintenance of 
myocytes in oxygenated cell media at 37 ° C. Cardioplegic arrest is incubation of myocytes with crystalloid 
cardioplegic solution (24 mEq/L K +) at 4 ° C for 2 hours. Vehicle is incubation of myocytes in oxygenated 
normothermic media containing Krebs buffer solution containing ethanol (0.01%). PMA is incubation of 
myocytes in normothermic, oxygenated media containing 10 9 mol/L of PMA for 3 minutes. 
PMA +Chelerythrine is incubation of myocytes in normothermic, oxygenated media containing PMA (10 -9 
mol/L) and chelerythrine (10 a tool/L) for 3 minutes. After the treatment protocols, indices of myocyte 
contractile function at steady-state were obtained. 
molecular grade formaldehyde for 10 minutes and then 
transferred toa stabilization buffer containing 1,4 Pepera- 
zinedithanesulfonic a id (PIPES) (65 mmot/L), HEPES 
(25 mmol/L), ethyleneglycol tetraacetic acid (EGTA) (10 
mmol/L), and MgCla (3 mmol/L). The myocytes were then 
incubated in the presence of a fluorescently conjugated 
PKC probe (B1ODIPY FL bis-indolylmaleimide; 100 
/xmol/L, B7485 Molecular Probes, Eugene, Ore.) 24 for 10 
minutes. Fluorescently conjugated bis-indolylmaleimide 
has been demonstrated previously to be membrane-per- 
meant, bind to the catalytic domain of PKC, and demon- 
strate translocation of PKC from the cytoplasm to mem- 
branes, z~ In preliminary studies, the concentration and 
incubation period for this PKC probe provided specific 
intracellular staining in isolated LV myocyte preparations. 
After the incubation step, the coverslips containing the 
myocytes were placed on glass slides containing an anti- 
fade glycerol solution (4%, 1,8 diazabicyclo[2.2.2]octane, 
Sigma). The myocyte preparations were then examined by 
means of confocal scanning microscopy (MRC-1000, Bio- 
Rad Laboratories, Hercules, Calif.) with excitation/emis- 
sion wavelength settings of 509/520, respectively. Myo- 
cytes were imaged at an original magnification of 600;< 
and images digitally captured at 1.0 /xm increments 
through the myocyte. A minimum of 25 myocytes were 
examined from each preparation. 
Data analysis. Indices of myocyte contractile function for 
the different reatment groups were compared by means of 
analysis of variance. If analysis of variance detected signifi- 
cant differences with respect o treatment groups, mean 
separation was performed with the use of Bonferroni 
bounds. All statistical procedures were performed with the 
use of the BMDP statistical software package (BMDP 
Statistical Software, Inc., Los Angeles, Calif.). Results are 
presented as mean + standard error of the mean. Values of 
p < 0.05 were considered statistically significant. 
Results 
Steady-state myocyte contractile function under 
normothermic conditions, after simulated cardiople- 
gic arrest with rewarming, and with PMA pretreat- 
ment followed by cardioplegic arrest and rewarming 
are presented in Table I. Indices of contractile 
function obtained under steady-state normothermic 
conditions are consistent with previous values ob- 
tained with the use of this myocyte preparation. 14-16 
After cardioplegic arrest and rewarming, steady- 
state myocyte percent and velocity of shortening 
were reduced by more than 40% from normother- 
mic control values. The reduction in myocy~e con- 
tractility after simulated cardioplegic arrest and 
rewarming is consistent with previous reports from 
this laboratory. 14-16 Pretreatment with PMA before 
cardioplegic arrest and rewarming resulted in im- 
proved indices of myocyte contractile function with 
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Table I. Steady-state myocyte contractile function after cardiopIegic arrest and rewarming: Effects of protein 
kinase C activation before cardioplegic arrest 
Normothermia CardiopIegia PMA/cardioplegia 
Percent shortening (%) 
Shortening velocity (p~m/sec) 
Relengthening velocity (/xm/sec) 
Total duration (msec) 
Time to peak contraction (msec) 
Time to 50% relaxation (msec) 
Number of cells 
4.5 _+ 0.2 2.1 -+0.1 ~" < 0.0001 4.3 + 0.2 
48.8 ± 2.0 22,3 -+ 1.6" < 0.0001 48.8 + 2.5 
46.7 ± 2.2 18,0 ± 1.5" < 0.0001 49.0 + 3.5 
482.5 -+ 9.8 617,7 -+ 36.0* < 0.0001 553.15 +- 21.9" 0.0058 
243.6 ± 7.2 306.8 ± 16.1" 0.0002 289.0 ± 13.7' 0.0038 
101.2 ± 3.3 157.9 ± 13.0" < 0.0001 !30.3 ± 9.6* 0.0039 
70 31 39 
Values are presented as mean -+ standard error of the mean. Normothem~ia, Untreated myocytes maintained at 37°C in media; Cardioplegia, ncubated with 
Krebs buffer containing ethanol (0.01%) followed by incubation with crystalloid cardioplegia (K +, 24 mEq/L) at 4°C for 2 hours followed by rewarming with 
media at 37°C for 5 minutes; PMA/cardioplegia, pretreatment with 10-9 rnol/L of phorbo112-myristate 13-acetate for 3 minutes followed by cardioplegic arrest 
with rewarming. 
Up < 0.05 versus normothermia. Values following the asterisk indicate specific p values for each comparison. 
subsequent reperfusion and rewarming. Specifically, 
myocyte percent shortening, shortening velocity, 
and velocity of relengthening were significantly in- 
creased from cardioplegia-alone values. More im- 
portant, these indices of contractile function with 
PMA pretreatment were similar to normothermic 
control values (p > 0.60). However. myocyte total 
duration of contraction, time to peak contraction, 
and time to 50% relaxation were prolonged with 
PMA pretreatment and cardioplegic arrest when 
compared with normothermic values. These results 
suggest hat pretreatment with PMA before simu- 
lated cardioplegic arrest protected indices of myo- 
cyte contractile function with subsequent reperfu- 
sion and rewarming, but defects in the temporal 
aspects of myocyte contractile process persisted. 
Co-incubation with chelerythrine and PMA before 
cardioplegic arrest and rewarming abolished the 
protective ffects of PMA pretreatment on steady- 
state myocyte shortening velocity (Fig. 3). In myo- 
cytes pretreated with chele~thrine before car- 
dioplegic arrest (n - 21), myocyte percent and 
velocity of shortening were similar to cardioplegia- 
alone values (2.5% z 0.2%, 26 _+ 3 ~m/sec, respec- 
tively). Therefore the protective ffects on myocyte 
contractile function with PMA pretreatment before 
cardioplegic arrest and rewarming were likely medi- 
ated by specific activation of PKC. 
To more carefully examine whether PMA pre- 
treatment in this isolated myocyte preparation in- 
duced PKC activation, we performed intracellular 
localization for PKC. In normothermic control myo- 
cytes, intense staining for PKC could be localize d to 
the cytosolic compartment. Specifically, a strong 
fluorescent signal corresponding to PKC was ob- 
served in the perinuclear egion and surrounding 
the myofilament array (Fig. 4). In these untreated 
control myocytes, minimal diffuse staining could be 
observed along the sarcolemma. In PMA-treated 
myocytes, the fluorescent signal for PKC within the 
perinuclear space could still be detected; however, a
strong punctate staining pattern was observed along 
the myocyte sarcolemma (Fig. 4). In all myocytes 
examined after PMA treatment, an intense fluores- 
cent signal could be readily detected along the 
cytosolic/sarcolemmal interface. This altered fluo- 
rescent staining pattern in PMA-treated myocytes 
is consistent with PKC activation and transloca- 
tion. al-24 In myocytes treated with both PMA and 
chelerythrine, the fluorescent staining for PKC was 
similar to that in normothermic control myocytes 
(Fig. 4). Specifically, strong cytosolic staining could 
be detected in perinuclear and myofilament com- 
partments with minimal diffuse staining along the 
sarcolemma. These results provide further evidence 
to suggest that PMA treatment caused PKC activa- 
tion in this isolated myocyte preparation. 
Discussion 
Cessation of myocardial contractile activity is 
commonly required for the conduct of many cardiac 
surgical procedures and is routinely achieved 
through the administration of a hypothermic, hy- 
perkalemic cardioplegic solution. However, tran- 
sient LV dysfunction can occur after cardioplegic 
arrest, which may persist in the early postoperative 
period. Transient, brief periods of myocardial isch- 
emia have been demonstrated to confer a protective 
effect o the myocardium with subsequent prolonged 
periods of ischemia; this protective ffect has been 
defined as the preconditioning phenomenon. ~-3 A 
proposed intracellular mechanism for the protective 
effects of preconditioning is activation of PKC. 7-1° 
Past studies have demonstrated that a brief interval 
of PKC activation before a prolonged period of 
ischemia provided protective ffects imilar to those 
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Fig. 3. A series ofexperiments was performed to determine 
more carefully whether the protective effect of pretreatment 
with PMA was due to specific activation f PKC. Accord- 
ingly, isolated myocytes w re incubated in the presence of 
both chelerythrine (10 6 tool/L), a specific inhibitor of 
PKC, 2° and PMA (10 -9 mogL) for 3 minutes and then 
subjected to cardioplegic arrest and rewarming. Two hours 
of simulated cardioplegic arrest and rewarming reduced 
steady-state myocyte shortening velocity compared with nor- 
mothermic values. Pretreatment with PMA (10 -9  mol/L) 
before cardioplegic arrest and rewarming restored steady- 
state myocyte shortening velocity to normothermic values. 
The protective effects of PMA pretreatment were abolished 
with co-incubation with chelerythrine and PMA. Thus the 
protective effects of PMA pretreatment were likely due to 
specific activation of PKC. *p < 0.05 versus normothermia. 
achieved by ischemic preconditioning. 7-m The 
present study was designed to determine whether a 
brief interval of PKC activation before prolonged 
cardioplegic arrest would provide protective effects 
on myocyte contractile function with subsequent 
reperfusion and rewarming. Using an isolated myo- 
cyte model of simulated cardioplegic arrest, we 
made two important observations. First, a brief 
period of PKC activation achieved through exposure 
of myocytes to the phorbol ester PMA before car- 
dioplcgic arrest provided protective ffects on myo- 
cyte contractile function with rewarming. Second, 
the protective ffects of PMA pretreatment before 
cardioplegic arrest and rewarming were abolished 
by concomitant treatment with a specific inhibitor of 
PKC. Therefore the present study provides direct 
evidence that a brief period of PKC activation 
C 
Fig. 4. To examine more carefully whether PMA pre- 
treatment in this isolated myocyte preparation i duced 
PKC activation, we used a fluorescent probe to perform 
intracellular localization. A, In control myocytes, intense 
staining for PKC could be localized to the cytoso!ic 
compartment. A strong fluorescent signal corresponding 
to PKC was observed in the perinuclear region and 
surrounding the myofilament array. B, In PMA-treated 
myocytes, the fluorescent signal for PKC within the pe- 
rinuclear space could still be detected, but a strong 
punctate staining pattern was observed along the myoeyte 
sarcolemma ( rrows). C, In myocytes treated with both 
PMA and chelerythrine, the fluorescent staining for PKC 
was similar to normothermic control myocytes. These 
results provided evidence to suggest that PMA treatment 
caused PKC activation and subsequent translocation i
this isolated myocyte preparation. All images were ob- 
tained with the use of scanning confocal microscopy with 
an image depth of 15/,m and an original magnification of 
600×. 
within the LV myocyte before cardioplegic arrest 
confers protective effects on myocyte contractile 
processes with subsequent reperfusion and rewarm- 
ing. 
In a past report, Illes and associates 4 demon- 
strated that preconditioning in the rabbit heart 
improved LV pump function after hypothermic car- 
dioplegic arrest and rewarming. A number of recent 
studies have provided evidence that n intracellular 
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event necessary for inducing the preconditioning 
phenomenon is through activation of PKC. 7-1°' 12, 13 
Past studies have demonstrated that precondition- 
ing can be successfully elicited in isolated myocyte 
systems.12, 13, 16-19 In a recent report from this labo- 
ratory, it was demonstrated that hypoxic precondi- 
tioning of isolated myocytes before simulated car- 
dioplegic arrest improved contractile function with 
subsequent reperfusion and rewarming. 16 However, 
it remained unclear whether PKC activation before 
cardioplegic arrest would provide similar protective 
effects with respect o myocyte contractile function. 
In the present study, treatment with the phorbol 
ester PMA before prolonged cardioplegic arrest, 
significantly improved indices of myocyte contractile 
function with subsequent reperfusion and rewarm- 
ing. Treatment of this isolated myocyte preparation 
with PMA caused a detectable intracellular shift in 
PKC from the cytoplasm to the sarcolemmal sur- 
face, consistent with PKC activation. 2>24 Further- 
more, co-treatment with a PKC inhibitor and PMA 
eliminated the protective ffects induced by PMA 
pretreatment. Taken together, the results from the 
present study build on past reports and provide 
direct evidence that induction of PKC activation in 
isolated myocytes immediately before cardioplegic 
arrest will result in improved contractile function 
with subsequent reperfusion and rewarming. 
Consistent with past reports, 25-28 simulated car- 
dioplegic arrest in an isolated LV myocyte system 
caused a significant reduction in the indices of 
myocyte contractile performance with subsequent 
reperfusion and rewarming. In the present study, a 
brief (3-minute) interval of PKC activation before 
the induction of cardioplegic arrest normalized 
myocyte percent and velocity of shortening with 
subsequent reperfusion and rewarming. This obser- 
vation suggests that activation of PKC within the 
myocyte provided protective ffects on myocyte ho- 
meostatic processes during the period of cardiople- 
gic arrest. Activation of PKC results in a number of 
intracellular events within the myocyte, which in- 
clude influencing ion exchange systems and pumps, 
activity of mitogen-activated protein kinases, phos- 
phorylation states of contractile proteins, and cy- 
toskeletal protein conformation. 21' 22, 25, 26 The acti- 
vation of PKC has also been shown to influence 
gene expression and myocardial growth proper- 
ties.21, 22 Results from the present study, as well as 
past reports, 7-1° demonstrated significant protective 
effects after only a brief period of PKC activation. 
Therefore the acute effects of PKC activation that 
were observed in the present study were probably 
not due to changes in transcriptional or translational 
processes, but more likely due to alterations in 
intracellular ionic homeostasis and phosphorylation 
states. PKC activational status has been demon- 
strated to influence the activity of the Na+/H + 
exchanger, which will cause intracellular alkaliniza- 
tion. 21'22 PKC activation has also been demon- 
strated to influence intracellular Ca +2 levels by 
modulating the function of the 1-type Ca +2 channel 
on the myocyte sarcolemma, 26 as well as the sarco- 
plasmic reticulum Ca+2-adenotriphosphatase. at Thus, 
in the present study, it is likely that PKC activation 
in isolated LV myocytes changed intracellular pH 
and Ca +2 levels, which provided a protective ffect 
when subjected to prolonged hypothermic, hy- 
perkalemic cardioplegic arrest. However, future 
studies that directly measure intracellular pH and 
Ca +2 with PKC activation during cardioplegic arrest 
will be necessary to directly examine this possibility. 
Pretreatment of isolated myocytes with the phor- 
bol ester PMA, and therefore activation of PKC, 
before cardioplegic arrest improved myocyte short- 
ening and velocity of shortening with subsequent 
reperfusion and rewarming. However, abnormalities 
in temporal indices of the contraction process, such 
as time to peak contraction, duration of contraction, 
and time to 50% relaxation, were prolonged with 
PMA pretreatment when compared with normo- 
thermic values. Myocyte percent shortening reflects 
the maximal extent of myofilament interaction and 
velocity of shortening reflects the rate of cross- 
bridge cycling. PMA pretreatment increased the 
time interval to peak myocyte contraction, but myo- 
cyte percent shortening was similar to normother- 
mic values. These findings suggest that PKC activa- 
tion before cardioplegic arrest likely influenced 
mechanisms by which cross-bridge cycling rates are 
translated into overall myocyte shortening. It has 
been demonstrated previously that PKC activation 
influences the phosphorylation state and orientation 
of a number of contractile and cytoskeletal pro- 
teins.21, 22, 25 Thus, in the present study, PKC pre- 
treatment may have altered cytoskeletal architec- 
ture within the myocyte, which in turn would 
influence sarcomere shortening to be translated to 
cell shortening. The present study demonstrated 
that an index of myocyte active relaxation, the 
time to 50% relaxation, remained prolonged with 
PMA pretreatment. The time to 50% relaxation 
reflects the period of cross-bridge release and 
Ca +2 resequest ra t ion  by the sarcoplasmic reticu- 
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lum. The findings of the present study suggest that 
the time necessary for cross-bridge release and 
the return of the myofilament array to a resting 
position was altered after cardioplegic arrest and 
could not be reversed by PMA pretreatment. PKC 
activation influences a number of Ca +2 homeo- 
static mechanisms within the myocyte. 21' 22, 25, 26 
However, whether the persistent abnormalities in
active relaxation with PMA pretreatment fol- 
lowed by cardioplegic arrest hat were observed in 
the present study were due to temporal changes in 
myocyte Ca +2 homeostatic properties remains 
unclear. In light of the findings from the present 
study and the spectrum of intracellular events that 
occur after PKC activation, future studies that 
more carefully examine Ca +2 homeostatic pro- 
cesses with PKC activation and cardfoplegic arrest 
are warranted. 
In the present study, PKC activation under nor- 
mothermic steady-state conditions reduced indices 
of myocyte contractile function. Karmazyn, Watson, 
and Moffat 27 demonstrated that PMA treatment in
rat heart preparations reduced indices of LV con- 
tractile performance. In studies of ischemic precon- 
ditioning in which a period of myocardial protection 
is conferred, the interval before the prolonged isch- 
emic insult is often associated with a condition 
described as "myocardial stunning. ''>3 Several past 
reports have suggested that a contributory intracel- 
lular mechanism for this "myocardial stunning" phe- 
nomenon is PKC activation. 713 Thus the reduction 
in myocyte contractile performance that was ob- 
served in the present study after the acute adminis- 
tration of the phorbol ester PMA, with subsequent 
PKC activation, was not unexpected. In fact, the 
dose of PMA that caused a decline in steady-state 
function was used as a criterion that significant PKC 
activation had occurred within the myocyte. TM19, 27 
However, it may be possible to develop aprotocol by 
which adequate PKC activation can be achieved to 
confer myocardial protection without a concomitant 
fall in contractile performance. Future studies with 
the myocyte model of simulated cardioplegic arrest 
described in the present study and in past re- 
ports, 14-16 but which more carefully address this 
issue, would be appropriate. 
Intracellular activation of PKC in most cell types 
is normally through the production of diacylglycerol, 
which is produced by a number of receptor-medi- 
ated events. 12' 21, 22, 26, 28, 29 Tumor-promoting phor- 
bol esters such as PMA are membrane permeable 
and have structures similar to diacylglycerol, which 
provide a means to activate PKC directly. TM 22, 29 In 
addition to phorbol esters being described as tumor- 
promoting agents, these compounds are not effi- 
ciently degraded by intrinsic enzymatic pathways 
and can cause a number of systemic effects. 29 Thus 
the clinical application of phorbol esters such as 
PMA to induce PKC activation within the LV 
myocardium is problematic. However, several sar- 
colemmal receptor transduction systems have been 
demonstrated to induced PKC activation. TM 22 For 
, example, activation of the adenosine receptor sys- 
tem(s) that are located within the myocyte sarco- 
lemma cause activation of PKC)' 12 Furthermore, 
Armstrong, Downey, and Ganote 12 demonstrated 
that the protective ffects of adenosine-receptor 
activation i  the setting of global ischemia could be 
abolished through inhibition of PKC activation. 12
Future studies that directly determine the relation- 
ship between the adenosine receptor and PKC 
activational states in the setting of cardioplegic 
arrest are warranted. 
The isolated myocyte model used in the present 
study provides an uncomplicated means by which to 
determine the direct effects of pretreatment strate- 
gies with simulated cardioplegic arrest on contrac- 
tile performance. Although this myocyte system has 
some advantages over an in vivo preparation, it has 
important limitations that must be recognized. The 
isolated myocyte system removes differences in 
loading conditions, neurohormonal activity, and the 
influence of nonmyocyte c ll populations that would 
be encountered in vivo after cardioplegic arrest and 
rewarming. Another important consideration is that 
this isolated myocyte system differs from in vivo 
preparations in which capillary diffusion distances 
are affected by coronary artery disease, hypertrophy, 
and nonuniform maintenance and control of tem- 
perature. The limitations of the isolated myocyte 
system must be recognized, and extrapolation f the 
results from these in vitro studies to in vivo condi- 
tions should be performed with caution. In the 
present study, a qualitative morphometric examina- 
tion was performed to determine the relative PKC 
activational state after PMA treatment. Although 
this portion of the study demonstrated that PMA 
treatment was associated with PKC transloeation 
and that this brief interval of PKC activation before 
cardioplegic arrest improved myocyte function with 
subsequent rewarming, quantitation of the degree 
and nature of PKC activation within the myocytes 
was not addressed. PKC is not a single entity but 
comprises a large family of kinases encoded by 
different genes. TM 22 PKC has been broadly catego- 
rized into three separate classes, based primarily on 
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Ca +2 sensitivity of the amino-terminal regulatory 
region. 22 At present, more than 10 isoforms of PKC 
have been identified, and the relative expression of 
these isoforms within the myocardium is an area of 
active investigation. 21 Therefore, on the basis of the 
findings of the present study, future studies that 
more carefully examine the specific isoforms of PKC 
which can be recruited to provide protective ffects 
in the setting of cardioplegic arrest would be appro- 
priate. Nevertheless, the results from this study 
demonstrated that an endogenous means of provid- 
ing improved myocardial protection during pro- 
longed hypothermic, hyperkalemic cardioplegic ar- 
rest can be achieved through a brief period of PKC 
activation. 
We appreciate the assistance of Latha Hebbar and 
Melissa Doscher in the execution of this project. 
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